We identified one single nucleotide polymorphism, rs12333226 (OR=1.41, P=3.97×10<sup>-7</sup>), five HLA amino acid polymorphisms in HLA-DRB1 (OR=0.89, P=7.51×10<sup>-6</sup>-8.57×10<sup>-6</sup>), and one two-digit classic HLA allele HLA-A*11 (OR=0.87, P=9.68×10<sup>-6</sup>) that were strongly associated with the risk of lung cancer.
Our results suggested that expressions of HLA-BW6 and HLA-DRB1*13 alleles may be predictable markers for response to chemotherapy in lung cancer patients.
HLA class I (HLA-A, -B, and -C) antigens and HLA class II (HLA-DRB1) alleles were determined in 36 patients with lung cancer, 35 patients with hematological malignancies, and 90 healthy controls.